AR124419A1 - INVISIBLE SAFE CELLS FOR THE IMMUNE SYSTEM - Google Patents
INVISIBLE SAFE CELLS FOR THE IMMUNE SYSTEMInfo
- Publication number
- AR124419A1 AR124419A1 ARP210103566A ARP210103566A AR124419A1 AR 124419 A1 AR124419 A1 AR 124419A1 AR P210103566 A ARP210103566 A AR P210103566A AR P210103566 A ARP210103566 A AR P210103566A AR 124419 A1 AR124419 A1 AR 124419A1
- Authority
- AR
- Argentina
- Prior art keywords
- mammalian cell
- genes
- hsv
- immune system
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: La célula de mamífero que comprende un gen de fusión B2M / HLA-E, que no comprende otros genes de B2M expresables y que tiene incorporaciones de al menos 4 genes de HSV-TK en ubicaciones distintas y conocidas, en donde al menos uno de dichos 4 genes de HSV-TK es un gen de TK-sr39. Reivindicación 9: Un método para producir una célula de mamífero implantable, que comprende las etapas de: proporcionar una célula de mamífero, incorporar al menos un gen de fusión B2M / HLA-E en dicha célula de mamífero, inactivar los genes de B2M nativa de dicha célula de mamífero, incorporar al menos 4 genes de HSV-TK en ubicaciones distintas y conocidas, en donde al menos uno de dichos 4 genes de HSV-TK es un gen de TK-sr39, opcionalmente diferenciar dicha célula de mamífero, de manera que se obtiene dicha célula de mamífero implantable.Claim 1: The mammalian cell comprising a B2M/HLA-E fusion gene, not comprising other expressible B2M genes, and having incorporations of at least 4 HSV-TK genes at known, distinct locations, where at least one of said 4 HSV-TK genes is a TK-sr39 gene. Claim 9: A method of producing an implantable mammalian cell, comprising the steps of: providing a mammalian cell, incorporating at least one B2M/HLA-E fusion gene into said mammalian cell, inactivating native B2M genes from said mammalian cell, incorporating at least 4 HSV-TK genes at distinct and known locations, wherein at least one of said 4 HSV-TK genes is a TK-sr39 gene, optionally differentiating said mammalian cell, such obtaining said implantable mammalian cell.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20215272 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124419A1 true AR124419A1 (en) | 2023-03-29 |
Family
ID=73855659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103566A AR124419A1 (en) | 2020-12-18 | 2021-12-17 | INVISIBLE SAFE CELLS FOR THE IMMUNE SYSTEM |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR124419A1 (en) |
| TW (1) | TW202242095A (en) |
| WO (1) | WO2022129472A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024008979A1 (en) | 2022-09-30 | 2024-01-11 | Novo Nordisk A/S | A sirp-alpha binding chimeric protein |
| WO2024161048A2 (en) | 2023-07-07 | 2024-08-08 | Novo Nordisk A/S | Cells with promoter targeted insertion |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003046141A2 (en) | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| JP2005512593A (en) | 2001-12-28 | 2005-05-12 | セルアーティス アーベー | Establishing a pluripotent human blastocyst-derived stem cell line |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| GB2445338A (en) | 2005-10-07 | 2008-07-02 | Cellartis Ab | A method for obtaining a xeno-free HBS cell line |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| JP2014513948A (en) | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β2 microglobulin deficient cells |
| CN105683361B (en) | 2013-08-30 | 2021-04-02 | 诺和诺德股份有限公司 | Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules |
| WO2017079673A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| WO2017144695A1 (en) | 2016-02-24 | 2017-08-31 | Novo Nordisk A/S | Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors |
| MA45491A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
| CN111194349B (en) | 2017-08-08 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | Chimeric antigen receptor mediated cell targeting |
| US20210123022A1 (en) * | 2018-06-12 | 2021-04-29 | The Regents Of The University Of California | Stem cell-engineered inkt cell-based off-the-shelf cellular therapy |
| EP3820993A1 (en) * | 2018-07-13 | 2021-05-19 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
| US20210214416A1 (en) * | 2018-10-01 | 2021-07-15 | Caribou Biosciences, Inc. | Suicide module compositions and methods |
-
2021
- 2021-12-17 TW TW110147425A patent/TW202242095A/en unknown
- 2021-12-17 AR ARP210103566A patent/AR124419A1/en unknown
- 2021-12-17 WO PCT/EP2021/086399 patent/WO2022129472A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| TW202242095A (en) | 2022-11-01 |
| WO2022129472A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124419A1 (en) | INVISIBLE SAFE CELLS FOR THE IMMUNE SYSTEM | |
| EA201991849A1 (en) | SYSTEM AND METHOD FOR EDITING A GENOM | |
| BR112020024863A2 (en) | RNA-guided nucleases, active fragments and variants thereof and methods of use | |
| Taylor et al. | Heterogeneity in the differentiation and function of memory B cells | |
| CL2021001034A1 (en) | Methods and compositions for ocular cell therapy | |
| MX2019000022A (en) | Veto cells generated from memory t cells. | |
| BR112019008560A2 (en) | artificial antigen-presenting cell, method for expanding tumor infiltrating lymphocytes, treating cancer with a population of tumor infiltrating lymphocytes and for assessing the power of tumor infiltrating lymphocytes, kit, tumor infiltrating lymphocyte population, and, combination | |
| AR107278A1 (en) | PROCEDURES FOR THE PRODUCTION OF T-LYMPHOCYTES AND T-LYMPHOCYTES PRODUCED BY THEM | |
| CL2017000528A1 (en) | Discovery and production of conditionally active biological proteins in the same production eukaryotic host cells | |
| BR112015027996A2 (en) | organoids comprising isolated renal cells and their uses | |
| BR112016028512A8 (en) | method of culturing a mammalian cell and method of producing a recombinant protein | |
| BR112021014645A2 (en) | Gene editing method | |
| CY1112351T1 (en) | TR1 CELL TAKING, SPECIFIC FOR FOOD ANTIGENS OR FOR SELF ANTIGENS FROM A PBMC POPULATION POPULATION | |
| AR109451A1 (en) | COMPOSITIONS AND METHODS TO PREPARE ANTIBODIES BASED ON THE USE OF EXPRESSION IMPROVERS LOCI | |
| BR112016012229A2 (en) | polypeptide production methods | |
| ECSP22051779A (en) | METHODS FOR IMPROVING CELL CULTURE WITH SPECIES-SPECIFIC OR GENDER-SPECIFIC PROTEINS AND APPLICATIONS THEREOF | |
| Braid et al. | Engineered mesenchymal cells improve passive immune protection against lethal Venezuelan equine encephalitis virus exposure | |
| Hjelm et al. | Autotransporter-based antigen display in bacterial ghosts | |
| CN104131018A (en) | Intracellular protein self-induction expression method | |
| BR112022005963A2 (en) | CELLS WITH SUSTAINED TRANSGENE EXPRESSION | |
| CY1122993T1 (en) | PRODUCTION METHOD FOR PLRIPOTENTIAL STEM CELLS HAVING AN ANTIGEN-SPECIFIC T CELL RECEPTOR GENE | |
| EA202191360A1 (en) | IMPROVED RIBOFLAVIN PREPARATION | |
| CL2011003104A1 (en) | Method for the elaboration of unsaturated fatty acids, based on the cultivation of a cell that expresses a heterologous polypeptide with esaturase / enoyl-coa reductase activity in the host cell, an elongase complex that comprises said polypeptide and the use thereof. | |
| MY195280A (en) | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability | |
| CO2024002315A2 (en) | Gene editing systems comprising an RNA guide targeting stathmin 2 (stmn2) and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |